Acer Therapeutics Welcomes Two New Members to its Board of Directors Nasdaq:ACER

Mr. Jason Amello and Ms. Michelle Griffin Join the Board

Acer Board Comprised of 7 Customers

CAMBRIDGE, Mass., Oct. 12, 2017 (World NEWSWIRE) — Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical enterprise centered on the acquisition, improvement and commercialization of therapies for critical rare and extremely-rare illnesses with critical unmet healthcare have to have, right now announced the appointments of Mr. Jason Amello and Ms. Michelle Griffin to Acer’s Board of Administrators. Mr. Amello and Ms. Griffin were appointed to the Audit Committee, with Ms. Griffin serving as Chairperson.

“We are happy to welcome Jason and Michelle as the newest customers to our Board. Each convey decades of monetary and business encounter and community enterprise functions knowledge,” said Stephen Aselage, Chairman of the Board of Acer. “Their perception will incorporate tremendous worth to our Board, and we seem ahead to their contributions as we proceed to execute on our improvement strategy and shift in the direction of filing of an NDA for our guide product or service applicant EDSIVO™.”

About Mr. Jason Amello
Mr. Amello is the Senior Vice President, Main Economical Officer, and Treasurer of Akebia Therapeutics, Inc. and has held the position since 2013. Prior to becoming a member of Akebia, Mr. Amello served as Executive Vice President, Main Economical Officer, and Treasurer of ZIOPHARM Oncology, Inc. from 2012 to 2013. From 2000 to 2011, Mr. Amello held different positions at Genzyme Corporation, most a short while ago as Senior Vice President, Company Controller, and Main Accounting Officer, and led the Strategic Economical Providers group by means of which he served as a vital advisor on all of Genzyme’s M&A and strategic transactions. Previously in his job, Mr. Amello put in 10 many years in the company advisory and assurance exercise of Deloitte, serving in different roles of expanding responsibility by means of senior supervisor. Mr. Amello at this time serves on the Board of Administrators of the New England Baptist Medical center, the place he is the Chair of the High quality of Treatment Committee and a member of the Finance and Financial investment Committee. Mr. Amello holds a BA from Boston Higher education and is a Accredited General public Accountant in the Commonwealth of Massachusetts.

About Ms. Michelle Griffin
Ms. Griffin at this time supplies consulting products and services to biotechnology businesses and boards of directors by means of her agency, Pacific Biotechnology Consulting Team. Ms. Griffin at this time serves on the board of directors and chair of the audit committee for PhaseRx, Inc. since February 2016 and as of August 2017 serves as chair of the board of directors for Universal Cells, Inc. Moreover, she serves on the board of directors of Virginia Mason Wellness Technique and Virginia Mason Health care Center. Ms. Griffin served as a member of the board of directors for Polynoma LLC from 2012 to 2014. She served as executive vice president, functions, and as main monetary officer at OncoGenex Prescribed drugs Inc. from January 2011 to March 2013. Prior to that, Ms. Griffin served as a member of the board of directors of OncoGenex Prescribed drugs Inc. from May 2004 to January 2011. She served as performing main executive, senior vice president and main operating officer at Trubion Prescribed drugs, Inc., a biopharmaceutical enterprise, from February 2006 until finally its acquisition in October 2010 by Emergent BioSolutions, Inc. From August 2005 to January 2006, Ms. Griffin served as senior vice president and main monetary officer of Dendreon Corporation, a biotechnology enterprise. From March 1995 to July 2005, she was utilized by Corixa Corporation, a biotechnology enterprise, and served as its main monetary officer from 1997 until finally 2005 when Corixa Corporation was acquired by GlaxoSmithKline plc. Prior to that, Ms. Griffin held numerous finance and strategic scheduling positions at The Boeing Organization. She been given a put up-graduate certificate in accounting and an MBA from Seattle University and a B.S. in statistics and advertising from George Mason University and has handed the qualified community accountant test.

About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical enterprise centered on the acquisition, improvement and commercialization of therapies for individuals with critical rare and extremely-rare illnesses with critical unmet healthcare have to have. Acer’s late-phase medical pipeline contains two candidates for significant genetic ailments for which there are couple or no Fda-authorised solutions: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle ailments (UCD) and Maple Syrup Urine Ailment (MSUD). There are no Fda-authorised prescription drugs for vEDS and MSUD and confined options for UCD, which collectively influence far more than 4,000 individuals in the United States. Acer’s merchandise have medical evidence-of-principle and mechanistic differentiation, and Acer intends to look for approval for them in the U.S. by employing the regulatory pathway set up below section 505(b)(2) of the Federal Food items, Drug, and Beauty Act, or FFDCA, that makes it possible for an applicant to depend for approval at minimum in element on third-occasion knowledge, which is anticipated to expedite the preparation, submission, and approval of a advertising application.

For far more details, go to www.acertx.com.

Forward-Looking Statements
This push release contains “forward-searching statements” that include significant challenges and uncertainties for applications of the risk-free harbor delivered by the Non-public Securities Litigation Reform Act of 1995.  All statements, other than statements of historical points, incorporated in this push release about strategy, potential functions, potential monetary position, potential income, projected fees, prospective buyers, options and objectives of management are ahead-searching statements. Illustrations of these types of statements involve, but are not confined to, statements relating to the possible for EDSIVO™ (celiprolol) and ACER-001 to safely and securely and effectively concentrate on illnesses the adequacy of the company’s cash to assistance its potential functions and its capability to productively initiate and total medical trials and regulatory submissions the nature, strategy and emphasis of the enterprise and the improvement, anticipated timeline and business possible of any product or service candidates of the enterprise. Acer may possibly not in fact achieve the options, have out the intentions or fulfill the expectations or projections disclosed in the ahead-searching statements and you should really not put undue reliance on these ahead-searching statements. These types of statements are based mostly on management’s current expectations and include challenges and uncertainties. Genuine final results and functionality could differ materially from those projected in the ahead-searching statements as a consequence of many aspects, such as, with out limitation, challenges and uncertainties involved with the capability to project potential money utilization and reserves necessary for contingent potential liabilities and company functions, the availability of sufficient methods of the enterprise to fulfill its company objectives and operational needs, the point that the final results of before scientific studies and trials may possibly not be predictive of potential medical demo final results, the protection and current market exclusivity delivered by Acer’s intellectual assets, challenges associated to the drug improvement and the regulatory approval approach and the influence of competitive merchandise and technological improvements. Acer disclaims any intent or obligation to update these ahead-searching statements to mirror activities or circumstances that exist soon after the date on which they were manufactured. You should really assessment supplemental disclosures we make in our filings with the Securities and Trade Fee, such as our Registration Assertion on Type S-4 which was declared successful on August 10, 2017, and our Quarterly Reviews on Type 10-Q and Once-a-year Report on Type 10-K. You may possibly access these paperwork for no demand at http://www.sec.gov.

Trader Get hold of:
Hans Vitzthum
LifeSci Advisors
Ph: 212-915-2568
hans@lifescieadvisors.com

Leave a Reply